Small Molecules

14 March 2013

Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI

14 March 2013

Neos Therapeutics, Inc. Announces FDA Accepts NDA Filing for Extended Release Amphetamine Polistirex for the Once-Daily Treatment of ADHD

14 March 2013

Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet Oncology

13 March 2013

Trophos launches first study of olesoxime in Multiple Sclerosis patients

13 March 2013

N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis

13 March 2013

Astellas Pharma Inc.: Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

13 March 2013

Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis

12 March 2013

Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

12 March 2013

Merck Provides Update on IMPROVE-IT Trial

12 March 2013

Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat

12 March 2013

ANAVEX 2-73 restores mitochondrial functionality, blocks cell death and oxidative stress, preventing onset of Alzheimer’s disease

12 March 2013

Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug

11 March 2013

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure

11 March 2013

Moberg Derma Discontinues Clinical Development of Limtop

11 March 2013

The Medicines Company’s Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel

11 March 2013

Gilead’s Ranexa Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 Diabetes

11 March 2013

Retrophin Announces Positive Results from Preclinical Studies of RE-024 for PKAN

11 March 2013

Cubist Obtains Remaining Rights to Ceftolozane from Astellas

11 March 2013

Telormedix enrols first patient for Phase II in bladder cancer

9 March 2013

Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions

9 March 2013

Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs

9 March 2013

Prana Details Data Showing That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

7 March 2013

Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes

7 March 2013

New Superiority Trial Showed LIVALO (pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults with Dyslipidemia versus Pravastatin 40 mg

7 March 2013

ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1

6 March 2013

Results from a phase IIa study evaluating Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients have been presented at CROI

6 March 2013

First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

6 March 2013

Depomed Provides Update on SEFELSA™ FDA Advisory Committee

6 March 2013

Belinostat BELIEF trial exceeds primary endpoint with encouraging response rate

6 March 2013

Nuvo Research announces FDA response to PENNSAID 2% NDA

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

CD73 Inhibitor Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Nectin-4-Targeted Immunotherapy Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TL1A Inhibitor Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective